Shopping Cart
Remove All
Your shopping cart is currently empty
Lupartumab Amadotin (Synonyms: BAY 1129980, Anti-C4.4a antibody-drug conjugates)
Catalog No. T9901A-1023 Copy Product Info
🥰Excellent
Lupartumab Amadotin (BAY 1129980) is an antibody-drug conjugate (ADC) composed of a fully human C4.4A (LYPD3) targeting monoclonal antibody (BAY 1135626) linked through a non-cleavable alkyl hydrazide linker to a novel, highly potent microtubule-disrupting cytotoxic auristatin derivative. Lupartumab Amadotin is utilized in research on non-small cell lung cancer.
Lupartumab Amadotin
Copy Product Info🥰Excellent
Catalog No. T9901A-1023
Synonyms BAY 1129980, Anti-C4.4a antibody-drug conjugates
Lupartumab Amadotin (BAY 1129980) is an antibody-drug conjugate (ADC) composed of a fully human C4.4A (LYPD3) targeting monoclonal antibody (BAY 1135626) linked through a non-cleavable alkyl hydrazide linker to a novel, highly potent microtubule-disrupting cytotoxic auristatin derivative. Lupartumab Amadotin is utilized in research on non-small cell lung cancer.
Lupartumab Amadotin
Cas No. 1640972-00-4
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Lupartumab Amadotin (BAY 1129980) is an antibody-drug conjugate (ADC) composed of a fully human C4.4A (LYPD3) targeting monoclonal antibody (BAY 1135626) linked through a non-cleavable alkyl hydrazide linker to a novel, highly potent microtubule-disrupting cytotoxic auristatin derivative. Lupartumab Amadotin is utilized in research on non-small cell lung cancer. |
| In vitro | Lupartumab Amadotin (BAY 1129980; 0-2 nM; 72 h) exhibits significant antiproliferative activity in cell lines with endogenous C4.4A expression. It also inhibits the proliferation of C4.4A-transfected A549 lung cancer cells, showing selectivity when compared to a non-targeting control ADC. |
| In vivo | Lupartumab Amadotin (BAY 1129980; 1.9-15 mg/kg; i.v.; Q4D×3) demonstrates antitumor activity in C4.4A-positive NCI-H292 and NCI-H322 NSCLC xenograft models. Additionally, Lupartumab Amadotin (BAY 1129980; 7.5 and 15 mg/kg; i.v.; Q4D×3) exhibits target-dependent antitumor efficacy in NSCLC patient-derived xenograft (PDX) models focusing on the C4.4A target. |
| Synonyms | BAY 1129980, Anti-C4.4a antibody-drug conjugates |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Target | C4.4A (LYPD3) |
| Cas No. | 1640972-00-4 |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Lupartumab Amadotin | purchase Lupartumab Amadotin | Lupartumab Amadotin cost | order Lupartumab Amadotin | Lupartumab Amadotin in vivo | Lupartumab Amadotin in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.